JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: GlobeNewswire
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/JSPR. Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were
Show less
Read more
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal InvestigationGlobeNewswire
- Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation [Yahoo! Finance]Yahoo! Finance
- Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study InvestigationGlobeNewswire
- JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire
- JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action LawsuitBusiness Wire
JSPR
Earnings
- 11/10/25 - Miss
JSPR
Sec Filings
- 12/2/25 - Form SCHEDULE
- 12/2/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- JSPR's page on the SEC website